The U.S. Food and Drug Administration (FDA) has granted orphan drug status to navenibart — the new generic name of Astria Therapeutics’ experimental therapy STAR-0215 — as a treatment for hereditary angioedema (HAE).
News
People with hereditary angioedema (HAE) in Japan with access to on-demand therapies alone can have a high rate of attack frequency — weekly or monthly — that associates with a poorer quality of life, a study in that country reports. Patients’ functioning, fears, and feelings of shame significantly linked…
A man who experienced recurrent episodes of tongue swelling was diagnosed with angioedema related to the use of an angiotensin-converting enzyme (ACE) inhibitor to treat high blood pressure, according to a case report. The patient’s symptoms eased after stopping treatment with the medication, lisinopril, with no recurrence of angioedema…
Treatment with Takhzyro (lanadelumab), an injectable antibody therapy, led to a mean reduction of 94.7% in monthly hereditary angioedema (HAE) attacks in adolescents with HAE, according to findings of a Phase 3 extension study. These results, which focused on a subgroup of 21 patients with type 1…
Orladeyo (berotralstat), an approved oral treatment to prevent attacks in hereditary angioedema (HAE) patients 12 years and older, is one step closer to being eligible for reimbursement under public drug plans in Canada, according to its developer, Biocryst Pharmaceuticals. Biocryst has successfully completed negotiations with the pan-Canadian…
The case of an elderly man who developed acquired angioedema associated with an underlying blood disorder called monoclonal gammopathy was described in a new report, with the researchers noting the condition is “very rare but serious.” The man’s angioedema was controlled only after the underlying monoclonal gammopathy was successfully…
Pharvaris said it plans to initiate a Phase 3 clinical trial by the end of the year to test an oral, extended-release tablet formulation of deucrictibant as a preventive, or prophylactic, treatment for hereditary angioedema (HAE). Called CHAPTER-3, the trial will assess the treatment’s safety and efficacy…
Treatment with deucrictibant continued to successfully prevent and treat swelling attacks in people with hereditary angioedema (HAE), according to new data from the open-label extension portions of two clinical trials. The findings, presented at the Bradykinin Symposium held in Berlin Sept. 5-6, support the use of deucrictibant…
The U.S. Food and Drug Administration (FDA) has agreed to review Kalvista Pharmaceuticals’ application seeking the approval of sebetralstat as an on-demand treatment for swelling attacks in people 12 and older with hereditary angioedema. Regulators expect to make their decision on the new drug application (NDA) the…
An algorithm that takes into account factors such as the frequency and location of swelling attacks may help distinguish chronic histaminergic angioedema (CHA), which is a form of angioedema, from chronic spontaneous urticaria (CSU), a disorder with similar symptoms. That’s according to a study, “Predictive…
Recent Posts
- Woman develops lung swelling from common antifungal medication: Report
- New study explores how adults with HAE recognize and manage feelings
- Sometimes, even our best efforts aren’t enough
- Ekterly use urged for kids with HAE 12 and older in new international guideline
- Why it’s important to maintain your own personal health information, part 1